SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung

David C. Underwood, Ruth R. Osborn, Steven Bochnowicz, +7

American Journal of Physiology-Lung Cellular and Molecular Physiology

AsthmaAntifibrotic TherapyInflammatory Lung DiseaseAdvanced Lung DiseaseLung Inflammation +21

SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence

David C. Underwood, Ruth R. Osborn, Charles J. Kotzer, +8

Journal of Pharmacology and Experimental Therapeutics

Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis

Alison M. Badger, Don E. Griswold, Rasesh Kapadia, +10

Arthritis & Rheumatism

Pyrimidinylimidazole inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes

Jerry L. Adams, Jeffrey C. Boehm, Shouki Kassis, +8

Bioorganic & Medicinal Chemistry Letters

BiochemistryMedicineLiver PhysiologyPyrimidinylimidazole InhibitorsHepatotoxicity +6

Nonpeptide Tachykinin Receptor Antagonists: I. Pharmacological and Pharmacokinetic Characterization of SB 223412, a Novel, Potent and Selective Neurokinin-3 Receptor Antagonist

Henry M. Sarau, Don E. Griswold, W. M. Potts, +9

Journal of Pharmacology and Experimental Therapeutics

Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity

Jerry L. Adams, Jeffrey C. Boehm, Timothy F. Gallagher, +7

Bioorganic & Medicinal Chemistry Letters

Medicinal ChemistryBiochemistryMedicineNatural SciencesMechanism Of Action +10

Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response

Don E. Griswold, Edward F. Webb, John Breton, +3

Inflammation

InflammationCellular PhasesAnti-inflammatoryAutoimmune DiseaseMedicine +8

SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.

Don E. Griswold, Edward F. Webb, Alison M. Badger, +6

PubMed

InflammationCytokineAnti-inflammatoryInterleukin-4 ProductionMedicine +11

SK&F 86002: A structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid

Don E. Griswold, Paul Marshall, Edward F. Webb, +7

Biochemical Pharmacology

InflammationAnti-inflammatoryOxysterolBiochemistryMedicine +8

Pharmacological Characterization of GSK573719 (Umeclidinium): A Novel, Long-Acting, Inhaled Antagonist of the Muscarinic Cholinergic Receptors for Treatment of Pulmonary Diseases

M Salmon, Mark A. Luttmann, James J. Foley, +13

Journal of Pharmacology and Experimental Therapeutics